Syros Pharmaceuticals, Inc

Founded in 2003, Biodel is a pharmaceutical company that develops novel formulations for therapeutic care solutions. It offers medicines for the treatment of various endocrine disorders, including diabetes and osteoporosis. The company uses VIAdel technology, which enables delivery of endocrine therapeutics into blood through various routes of administration. Biodel also offers VIAject, which is an injectable human insulin product. It provides VIAtab, which is an oral human insulin product. The company offers VIAmass and VIAcal that formulates parathyroid hormone and salmon calcitonin for the treatment of osteoporosis. Additionally, Biodel provides a variety of clinical trial services and organizes various community events.

Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website